Literature DB >> 10600600

In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir.

J M Barnett1, A Cadman, F M Burrell, S H Madar, A P Lewis, M Tisdale, R Bethell.   

Abstract

We describe the in vitro selection and characterisation of virus derived from B/Beijing/1/87 passaged in the presence of zanamivir. During zanamivir passage, the phenotype of virus isolates was either drug dependent or drug resistant in plaque reduction assays. The susceptibility of the neuraminidase of the drug-dependent isolates was unchanged from that of the wild-type enzyme. The drug-dependent isolates contained two mutations in the viral haemagglutinin: V90A, close to the proposed secondary sialic acid-binding site, and L240Q, close to the primary sialic acid-binding site. Virus isolates that were drug resistant contained the same mutations in the haemagglutinin but also contained the mutation E116G in the neuraminidase. For the drug-dependent viruses, zanamivir susceptibility could not be measured because plaque numbers increased with increasing drug concentration. The in vitro zanamivir susceptibility of drug-resistant viruses was lower than that of the wild-type virus by a factor of 275- to >2532-fold. Neuraminidase containing the E116G mutation has a 33-fold lower affinity for zanamivir than the wild-type enzyme. The finding that the same haemagglutinin mutations are found in both drug-dependent and drug-resistant viruses confirms that the same changes to the receptor binding function can contribute to both phenotypes. This observation demonstrates the interplay between the influenza virus haemagglutinin and neuraminidase in escape from zanamivir inhibition in vitro. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600600     DOI: 10.1006/viro.1999.0058

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.

Authors:  Gallen B Triana-Baltzer; Rebecca L Sanders; Maria Hedlund; Kellie A Jensen; Laura M Aschenbrenner; Jeffrey L Larson; Fang Fang
Journal:  J Antimicrob Chemother       Date:  2010-11-21       Impact factor: 5.790

Review 2.  Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Authors:  Andrew J Burnham; Tatiana Baranovich; Elena A Govorkova
Journal:  Antiviral Res       Date:  2013-09-04       Impact factor: 5.970

3.  In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.

Authors:  Aeron C Hurt; Jessica K Holien; Ian G Barr
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191

4.  Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Authors:  Andrew J Burnham; Tatiana Baranovich; Bindumadhav M Marathe; Jianling Armstrong; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

5.  A 3D-RISM/RISM study of the oseltamivir binding efficiency with the wild-type and resistance-associated mutant forms of the viral influenza B neuraminidase.

Authors:  Jiraphorn Phanich; Thanyada Rungrotmongkol; Daniel Sindhikara; Saree Phongphanphanee; Norio Yoshida; Fumio Hirata; Nawee Kungwan; Supot Hannongbua
Journal:  Protein Sci       Date:  2015-06-22       Impact factor: 6.725

6.  A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity.

Authors:  M T Murrell; M Porotto; O Greengard; N Poltoratskaia; A Moscona
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA.

Authors:  David Jackson; Andrew Cadman; Thomas Zurcher; Wendy S Barclay
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

8.  In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.

Authors:  Akhteruzzaman Molla; Warren Kati; Robert Carrick; Kevin Steffy; Yan Shi; Debra Montgomery; Nanette Gusick; Vincent S Stoll; Kent D Stewart; Teresa I Ng; Clarence Maring; Dale J Kempf; William Kohlbrenner
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

9.  Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza.

Authors:  Phillip J Yates; Nalini Mehta; Joseph Horton; Margaret Tisdale
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

10.  Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.

Authors:  Yan Wu; Feng Gao; Jianxun Qi; Yuhai Bi; Lifeng Fu; Sankar Mohan; Yuhang Chen; Xuebing Li; B Mario Pinto; Christopher J Vavricka; Po Tien; George F Gao
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.